Public advisory - M-Eslon (morphine sulfate) ER capsules: One lot recalled as some bottles labelled as M-Eslon 30 mg may contain 60 mg capsules, which may pose an overdose risk

OTTAWA, ON, Sept. 27, 2024 /CNW/ -

Summary

M-Eslon (morphine sulfate) ER capsules (CNW Group/Health Canada (HC))

• Product: M-Eslon (morphine sulfate) bottles labelled to contain 30 mg extended-release capsules may contain 60 mg extended-release capsules
• Issue: Health products – Product safety
• What to do: Check your M-Eslon (morphine sulfate) medication bottle or package. If your prescription is for 30 mg capsules and the bottle contains 60 mg capsules, or if you are unsure, do not take these capsules and return them to your pharmacy. If you or someone you are caring for is experiencing an overdose (symptoms are described below), call 911 immediately and seek immediate medical attention

Images

Affected products

Product	DIN	Lot number	Expiry date
M-Eslon (morphine sulfate) extended release capsules – bottles from the manufacturer are labelled as 30 mg	02019949	43885	04/2026

Issue

Ethypharm Inc. is recalling one lot of M-Eslon (morphine sulfate) extended release (ER) capsules because some bottles labelled as M-Eslon 30 mg ER may contain 60 mg capsules. This issue could lead to patients receiving a 60 mg dose instead of their prescribed 30 mg dose, which could result in an overdose and pose serious health risks.

M-Eslon is a prescription opioid drug used by adults for long-term pain management when pain is severe enough to require daily, around-the-clock painkillers and other treatment options are not able to treat the pain.

The 60 mg capsule has "60" and "M-ESLON" printed on it. The capsule has an opaque orange cap and a clear bottom.

The 30 mg capsule has "30" and "M-ESLON" printed on it. The capsule has an opaque pink cap and a clear bottom.

Taking too much morphine or suddenly increasing the dose could potentially lead to an overdose, which can be life-threatening. Symptoms of morphine overdose may include: confusion, dizziness, drowsiness, difficulties waking up, small (pinpoint) pupils, slow heartbeat, slow and difficult breathing, cold and clammy skin, fainting, seizure, coma and death.

Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.

What you should do

• Check your M-Eslon (morphine sulfate) medication bottle or package. If your prescription is for 30 mg, the capsules should be pink and clear. If it contains 60 mg capsules (orange and clear), or if you are unsure, do not take these capsules and contact your pharmacy immediately. Your pharmacist will check the capsules and provide you with a replacement if needed. Return the affected product to your pharmacy for proper disposal.
• Call 911 immediately and seek immediate medical attention if you or someone you are caring for is experiencing an overdose (e.g., slow breathing, drowsiness, or difficulties waking up).
• If an overdose is suspected, administer naloxone nasal spray or injection without delay. Give a repeat dose after 2 to 3 minutes if the person has not woken up or their breathing has not improved.
• Contact your health care professional if you have taken the wrong dose of your medication and have any health concerns.
• If you have questions about this recall contact Ethypharm Inc. by calling 1-855-694-0151, or by emailing [email protected].
• Report any health product-related side effects or complaints to Health Canada.

Additional information for health professionals:

• Health care professionals, such as pharmacists, should check bottles labelled as M-Eslon (morphine sulfate) 30 mg extended release (ER) capsules before dispensing to make sure they do not contain M-Eslon 60 mg ER capsules. Report any unusual bottles or other issues to the company and to Health Canada.

Également disponible en français

SOURCE Health Canada (HC)

Media Enquiries: Health Canada, [phone], [email protected]; Public Enquiries: [phone], 1-866 225-0709, [email protected]